Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma

Roberto Crocchiolo, F. Fallanca, G. Giovacchini, A. J M Ferreri, A. Assanelli, C. Verona, A. Pescarollo, M. Bregni, M. Ponzoni, L. Gianolli, F. Fazio, F. Ciceri

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The role of 18FDG-PET/CT during follow-up of patients affected by Hodgkin's lymphoma (HL) in complete remission after treatment is not fully elucidated, since a wide use of 18F fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in this setting could be limited by a relative high rate of false-positive results. Herein, we summarize a retrospective analysis of 27 patients with Hodgkin's lymphoma in complete remission after the first-line (n=20) or salvage (n=7) therapy receiving serial 18FDG-PET/CT scans during follow-up. Out of 165 scans, 13 were suspected for relapse, which was confirmed in seven patients. All relapses were correctly identified by 18FDG-PET/ CT positivity, with a 100% sensitivity; false-positive rate was 46% and negative predictive value was 100%. True-positive findings were mostly associated with multiple sites, subdiaphragmatic involvement, and/or previous sites of disease. According to our results, we conclude that performing routine PET/CT scan during follow-up of those patients who are at high risk of relapse would be advisable, although caution must be adopted when interpreting PET/CT results due to the relatively high rate of false-positive findings. If FDG abnormal uptake is present at multiple nodal sites, subdiaphragmatic lymph nodes, or previous sites of disease, histological verification of PET abnormal findings is warranted.

Original languageEnglish
Pages (from-to)1229-1236
Number of pages8
JournalAnnals of Hematology
Volume88
Issue number12
DOIs
Publication statusPublished - 2009

Fingerprint

Fluorodeoxyglucose F18
Hodgkin Disease
Recurrence
Lymph Nodes
Positron Emission Tomography Computed Tomography
Therapeutics

Keywords

  • FDG-PET/CT
  • Follow-up
  • Hodgkin's lymphoma
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. / Crocchiolo, Roberto; Fallanca, F.; Giovacchini, G.; Ferreri, A. J M; Assanelli, A.; Verona, C.; Pescarollo, A.; Bregni, M.; Ponzoni, M.; Gianolli, L.; Fazio, F.; Ciceri, F.

In: Annals of Hematology, Vol. 88, No. 12, 2009, p. 1229-1236.

Research output: Contribution to journalArticle

Crocchiolo, Roberto ; Fallanca, F. ; Giovacchini, G. ; Ferreri, A. J M ; Assanelli, A. ; Verona, C. ; Pescarollo, A. ; Bregni, M. ; Ponzoni, M. ; Gianolli, L. ; Fazio, F. ; Ciceri, F. / Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. In: Annals of Hematology. 2009 ; Vol. 88, No. 12. pp. 1229-1236.
@article{0767aa8e4c554ae59803744f22db98c7,
title = "Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma",
abstract = "The role of 18FDG-PET/CT during follow-up of patients affected by Hodgkin's lymphoma (HL) in complete remission after treatment is not fully elucidated, since a wide use of 18F fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in this setting could be limited by a relative high rate of false-positive results. Herein, we summarize a retrospective analysis of 27 patients with Hodgkin's lymphoma in complete remission after the first-line (n=20) or salvage (n=7) therapy receiving serial 18FDG-PET/CT scans during follow-up. Out of 165 scans, 13 were suspected for relapse, which was confirmed in seven patients. All relapses were correctly identified by 18FDG-PET/ CT positivity, with a 100{\%} sensitivity; false-positive rate was 46{\%} and negative predictive value was 100{\%}. True-positive findings were mostly associated with multiple sites, subdiaphragmatic involvement, and/or previous sites of disease. According to our results, we conclude that performing routine PET/CT scan during follow-up of those patients who are at high risk of relapse would be advisable, although caution must be adopted when interpreting PET/CT results due to the relatively high rate of false-positive findings. If FDG abnormal uptake is present at multiple nodal sites, subdiaphragmatic lymph nodes, or previous sites of disease, histological verification of PET abnormal findings is warranted.",
keywords = "FDG-PET/CT, Follow-up, Hodgkin's lymphoma, Relapse",
author = "Roberto Crocchiolo and F. Fallanca and G. Giovacchini and Ferreri, {A. J M} and A. Assanelli and C. Verona and A. Pescarollo and M. Bregni and M. Ponzoni and L. Gianolli and F. Fazio and F. Ciceri",
year = "2009",
doi = "10.1007/s00277-009-0752-4",
language = "English",
volume = "88",
pages = "1229--1236",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma

AU - Crocchiolo, Roberto

AU - Fallanca, F.

AU - Giovacchini, G.

AU - Ferreri, A. J M

AU - Assanelli, A.

AU - Verona, C.

AU - Pescarollo, A.

AU - Bregni, M.

AU - Ponzoni, M.

AU - Gianolli, L.

AU - Fazio, F.

AU - Ciceri, F.

PY - 2009

Y1 - 2009

N2 - The role of 18FDG-PET/CT during follow-up of patients affected by Hodgkin's lymphoma (HL) in complete remission after treatment is not fully elucidated, since a wide use of 18F fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in this setting could be limited by a relative high rate of false-positive results. Herein, we summarize a retrospective analysis of 27 patients with Hodgkin's lymphoma in complete remission after the first-line (n=20) or salvage (n=7) therapy receiving serial 18FDG-PET/CT scans during follow-up. Out of 165 scans, 13 were suspected for relapse, which was confirmed in seven patients. All relapses were correctly identified by 18FDG-PET/ CT positivity, with a 100% sensitivity; false-positive rate was 46% and negative predictive value was 100%. True-positive findings were mostly associated with multiple sites, subdiaphragmatic involvement, and/or previous sites of disease. According to our results, we conclude that performing routine PET/CT scan during follow-up of those patients who are at high risk of relapse would be advisable, although caution must be adopted when interpreting PET/CT results due to the relatively high rate of false-positive findings. If FDG abnormal uptake is present at multiple nodal sites, subdiaphragmatic lymph nodes, or previous sites of disease, histological verification of PET abnormal findings is warranted.

AB - The role of 18FDG-PET/CT during follow-up of patients affected by Hodgkin's lymphoma (HL) in complete remission after treatment is not fully elucidated, since a wide use of 18F fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in this setting could be limited by a relative high rate of false-positive results. Herein, we summarize a retrospective analysis of 27 patients with Hodgkin's lymphoma in complete remission after the first-line (n=20) or salvage (n=7) therapy receiving serial 18FDG-PET/CT scans during follow-up. Out of 165 scans, 13 were suspected for relapse, which was confirmed in seven patients. All relapses were correctly identified by 18FDG-PET/ CT positivity, with a 100% sensitivity; false-positive rate was 46% and negative predictive value was 100%. True-positive findings were mostly associated with multiple sites, subdiaphragmatic involvement, and/or previous sites of disease. According to our results, we conclude that performing routine PET/CT scan during follow-up of those patients who are at high risk of relapse would be advisable, although caution must be adopted when interpreting PET/CT results due to the relatively high rate of false-positive findings. If FDG abnormal uptake is present at multiple nodal sites, subdiaphragmatic lymph nodes, or previous sites of disease, histological verification of PET abnormal findings is warranted.

KW - FDG-PET/CT

KW - Follow-up

KW - Hodgkin's lymphoma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=70350274590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350274590&partnerID=8YFLogxK

U2 - 10.1007/s00277-009-0752-4

DO - 10.1007/s00277-009-0752-4

M3 - Article

C2 - 19468730

AN - SCOPUS:70350274590

VL - 88

SP - 1229

EP - 1236

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 12

ER -